19-41414045-C-T

Variant summary

Our verdict is Benign. Variant got -18 ACMG points: 0P and 18B. BP4_ModerateBP6_Very_StrongBS1BS2

The NM_000709.4(BCKDHA):​c.376-4C>T variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00208 in 1,613,302 control chromosomes in the GnomAD database, including 44 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.0015 ( 6 hom., cov: 32)
Exomes 𝑓: 0.0021 ( 38 hom. )

Consequence

BCKDHA
NM_000709.4 splice_region, intron

Scores

2
Splicing: ADA: 0.0001741
2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:7

Conservation

PhyloP100: 1.57
Variant links:
Genes affected
BCKDHA (HGNC:986): (branched chain keto acid dehydrogenase E1 subunit alpha) The branched-chain alpha-keto acid (BCAA) dehydrogenase (BCKD) complex is an innter mitochondrial enzyme complex that catalyzes the second major step in the catabolism of the branched-chain amino acids leucine, isoleucine, and valine. The BCKD complex consists of three catalytic components: a heterotetrameric (alpha2-beta2) branched-chain alpha-keto acid decarboxylase (E1), a dihydrolipoyl transacylase (E2), and a dihydrolipoamide dehydrogenase (E3). This gene encodes the alpha subunit of the decarboxylase (E1) component. Mutations in this gene result in maple syrup urine disease, type IA. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Sep 2009]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -18 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.41).
BP6
Variant 19-41414045-C-T is Benign according to our data. Variant chr19-41414045-C-T is described in ClinVar as [Benign]. Clinvar id is 93359.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr19-41414045-C-T is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population sas. gnomad4 allele frequency = 0.00155 (236/152310) while in subpopulation SAS AF= 0.0222 (107/4826). AF 95% confidence interval is 0.0188. There are 6 homozygotes in gnomad4. There are 147 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 6 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BCKDHANM_000709.4 linkc.376-4C>T splice_region_variant, intron_variant Intron 3 of 8 ENST00000269980.7 NP_000700.1 P12694-1A0A024R0K3
BCKDHANM_001164783.2 linkc.376-4C>T splice_region_variant, intron_variant Intron 3 of 8 NP_001158255.1 P12694Q59EI3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BCKDHAENST00000269980.7 linkc.376-4C>T splice_region_variant, intron_variant Intron 3 of 8 1 NM_000709.4 ENSP00000269980.2 P12694-1
ENSG00000255730ENST00000540732.3 linkc.478-4C>T splice_region_variant, intron_variant Intron 4 of 9 2 ENSP00000443246.1 F5H5P2

Frequencies

GnomAD3 genomes
AF:
0.00154
AC:
234
AN:
152192
Hom.:
6
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00151
Gnomad ASJ
AF:
0.00691
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.0217
Gnomad FIN
AF:
0.0000942
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.000970
Gnomad OTH
AF:
0.00143
GnomAD3 exomes
AF:
0.00359
AC:
899
AN:
250502
Hom.:
10
AF XY:
0.00467
AC XY:
633
AN XY:
135678
show subpopulations
Gnomad AFR exome
AF:
0.000124
Gnomad AMR exome
AF:
0.00159
Gnomad ASJ exome
AF:
0.00736
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0208
Gnomad FIN exome
AF:
0.000139
Gnomad NFE exome
AF:
0.000850
Gnomad OTH exome
AF:
0.00523
GnomAD4 exome
AF:
0.00214
AC:
3122
AN:
1460992
Hom.:
38
Cov.:
34
AF XY:
0.00275
AC XY:
1998
AN XY:
726808
show subpopulations
Gnomad4 AFR exome
AF:
0.000120
Gnomad4 AMR exome
AF:
0.00159
Gnomad4 ASJ exome
AF:
0.00662
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0217
Gnomad4 FIN exome
AF:
0.000208
Gnomad4 NFE exome
AF:
0.000722
Gnomad4 OTH exome
AF:
0.00245
GnomAD4 genome
AF:
0.00155
AC:
236
AN:
152310
Hom.:
6
Cov.:
32
AF XY:
0.00197
AC XY:
147
AN XY:
74468
show subpopulations
Gnomad4 AFR
AF:
0.000241
Gnomad4 AMR
AF:
0.00150
Gnomad4 ASJ
AF:
0.00691
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.0222
Gnomad4 FIN
AF:
0.0000942
Gnomad4 NFE
AF:
0.000970
Gnomad4 OTH
AF:
0.00142
Alfa
AF:
0.00157
Hom.:
1
Bravo
AF:
0.000990
Asia WGS
AF:
0.00664
AC:
23
AN:
3478
EpiCase
AF:
0.00125
EpiControl
AF:
0.00107

ClinVar

Significance: Benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:2
Jan 31, 2017
Eurofins Ntd Llc (ga)
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Apr 25, 2016
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Maple syrup urine disease Benign:2
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Jan 01, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

BCKDHA-related disorder Benign:1
Feb 22, 2019
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Maple syrup urine disease type 1A Benign:1
Sep 16, 2020
Natera, Inc.
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.41
CADD
Benign
8.9
DANN
Benign
0.87

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
0.00017
dbscSNV1_RF
Benign
0.018
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs199725420; hg19: chr19-41919950; API